Sickle cell gene therapies offer new hope, but access remains a major challenge

FDA-approved gene therapies for sickle cell disease offer a chance to help patients, but factors including cost and access have slowed their use.

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.cnbc.com)